Stephanie Duatschek - 05 Aug 2026 Form 3 Insider Report for Emergent BioSolutions Inc. (EBS)

Reporting relationship: EVP, CGO
Issuer ticker: EBS
Reported as of: 05 Aug 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 12 Aug 2026, 09:16:40 UTC
Source filing: View source filing
Reporting owner signature: /s/ Richard S. Lindahl, Attorney-in-fact

Key filing fact

Stephanie Duatschek filed Form 3 for Emergent BioSolutions Inc. (EBS) on 12 Aug 2026.

Key facts

This page summarizes Stephanie Duatschek's Form 3 filing for Emergent BioSolutions Inc. (EBS).
0 reported transactions and 7 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 09:16.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002149575 Primary reporting owner

Duatschek Stephanie

Relationship: EVP, CGO
Address: 300 PROFESSIONAL DRIVE, GAITHERSBURG
Signature: /s/ Richard S. Lindahl, Attorney-in-fact
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EBS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 197,416
Date: 05 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EBS holding Derivative

Employee Stock Option (Right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,772
Exercise price: $59.07
Footnotes: F2

EBS holding Derivative

Employee Stock Option (Right to buy) (Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,250
Exercise price: $41.38
Footnotes: F3

EBS holding Derivative

Employee Stock Option (Right to buy) (Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,308
Exercise price: $11.66
Footnotes: F4

EBS holding Derivative

Employee Stock Option (Right to buy) (Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,231
Exercise price: $8.39
Footnotes: F5

EBS holding Derivative

Employee Stock Option (Right to buy) (Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $2.33
Footnotes: F6

EBS holding Derivative

Employee Stock Option (Right to buy) (Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 62,500
Exercise price: $5.80
Footnotes: F7

EBS holding Derivative

Employee Stock Option (Right to buy) (Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,834
Exercise price: $8.99
Footnotes: F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Consists of 55,639 shares of common stock and 141,777 unvested RSUs from the Emergent Stock Incentive Plan. Each RSU represents a right to receive one share of common stock. The RSUs vest in three equal installments annually on the day prior to the anniversary date of the grant.

Footnote F2

Granted on July 9, 2021 and as of the date of this filing all of the shares underlying the option are vested and exercisable.

Footnote F3

Granted on March 1, 2022 and as of the date of this filing all of the shares underlying the option are vested and exercisable.

Footnote F4

Granted on March 6, 2023 and as of the date of this filing all of the shares underlying the option are vested and exercisable.

Footnote F5

Granted on June 9, 2023 and as of the date of this filing all of the shares underlying the option are vested and exercisable.

Footnote F6

Granted on March 13, 2024 and vests in three installments beginning on the day prior to the anniversary date of the grant. As of the date of this filing, 83,250 of the shares underlying the option are vested and exercisable.

Footnote F7

Granted on March 6, 2025 and vests in three installments beginning on the day prior to the anniversary date of the grant. As of the date of this filing, 20,813 of the shares underlying the option are vested and exercisable.

Footnote F8

Granted on March 3, 2026 and vests in three installments beginning on the day prior to the anniversary date of the grant.

SEC remarks

Exhibit list: Ex 24.1 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .